JPH09509654A - サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物 - Google Patents
サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物Info
- Publication number
- JPH09509654A JPH09509654A JP7519939A JP51993995A JPH09509654A JP H09509654 A JPH09509654 A JP H09509654A JP 7519939 A JP7519939 A JP 7519939A JP 51993995 A JP51993995 A JP 51993995A JP H09509654 A JPH09509654 A JP H09509654A
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- furyloxy
- benzamide
- tetrahydro
- dichloropyrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/247—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I (式中、 R1は場合により置換された低級アルキル基であり; R2は場合により置換されたオキサ脂肪族基であり; R3は場合により置換されたアリール基であるかまたは場合により置換されたヘ テロアリール基であり; Q1、Q2およびQ3は独立して窒素、CXまたはCHであり; Z1は酸素または硫黄であり; Z2は−CH=CH−、−C三C−、−CH2−CZ−、−CZCH2−、−CZ −CZ−、−CH2−NH−、−CH2−O−、−CH2−S−、−CX2−O−、 −CZNH−、−NH−CH2−、−O−CH2−、−SCH2−、−SOCH2− 、−SO2CH2−、−O−CX2−、−O−CZ−、−NH−CZ−、−N=N −、−NH−SO2−、−SO2−NH−、−CZ−CZ−NH−、−NH−CO −O−、−O−CO−NH−または−NH−CO−NH−であり; Zは酸素または硫黄であり;そして Xはハロである) で示される化合物またはそれらのN−オキシド或いはそれらの薬学的に許容され る塩。 2.R2がテトラヒドロフリルまたはテトラヒドロピラニルである請求項1に 記載の化合物。 3.R2がテトラヒドロ−3−フリルである請求項2に記載の化合物。 4.Z1が酸素である請求項1〜3のいずれか一項に記載の化合物。 5.R1がハロによって置換されている請求項1〜4のいずれか一項に記載の 化合物。 6.R1が、Z1に結合しているR1の位置で一つまたはそれ以上のハロによっ て置換されている請求項5に記載の化合物。 7.R3が、2の位置でまたは2と6の両方の位置で置換されたフェニルであ る請求項1〜6のいずれか一項に記載の化合物。 8.R3が、Z2に結合しているR3の位置に隣接する一つまたは両方の位置で 置換されたヘテロアリールである請求項1〜6のいずれか一項に記載の化合物。 9.R3が、3,5−ジハロ−ピリド−4−イルまたはそれらのN−オキシド である請求項8に記載の化合物。 10.Z2が−CZNH−であり、そしてR1が場合によりハロによって置換さ れた低級アルキルである請求項1〜9のいずれか一項に記載の化合物。 11.Z2が−CZNH−であり、そしてR2がテトラヒドロフリルまたはテト ラヒドロピラニルである請求項1〜10のいずれか一項に記載の化合物。 12.Z2が−CZNH−であり、そしてR3が、Z2に結合しているR3の位置 に隣接する一つもしくは両方の位置で置換されている、置換フェニルまたは置換 ピリジルである請求項1〜11のいずれか一項に記載の化合物。 13.Z2が−CZNH−であり、そしてZ1が酸素である請求項1〜12のい ずれか一項に記載の化合物。 14.Z2が−CH=CH−、−C三C−、−CH2−CZ−、−CZ−CZ− 、−CH2−NH−、−CH2−O−、−CH2−S−、−CX2−O−、−NH− CH2−、−O−CH2−、−SCH2−、−SOCH2−、−SO2CH2−、−O −CX2−、−O−CZ−、−NH−CZ−、−N=N−、−NH−SO2−、− SO2−NH−、−CZ−CZ−NH−、−NH−CO−O−、−O−CO−N H−または−NH−CO−NH−である請求項1〜9のいずれか一項に記載の化 合物。 15.Q1とQ2とQ3のすべてがCHを表す請求項1〜14のいずれか一項に 記載の化合物。 16.Q1とQ2が独立して窒素またはCXであり、そしてQ3がCHである請 求項1〜14のいずれか一項に記載の化合物。 17.Q1とQ3が各々CHを表し、そしてQ2が窒素またはそれらのN−オキ シドである請求項1〜14のいずれか一項に記載の化合物。 18.Q1とQ3が各々CHを表し、そしてQ2がCXである請求項1〜14の いずれか一項に記載の化合物。 19.CXがCFである請求項1〜14、16または18のいずれか一項に記 載の化合物。 20.(±)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3−(テト ラヒドロ−4−ピラニルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−メト キシ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−4−ピリジル)−4−ジフルオロメトキシ− 3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−ピリジノ)−4−ジフルオロ メトキシ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジフルオロフェニル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−(2−クロロ−6−フルオロフェニル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)ベンズアミド; N−(2−トリフルオロメチルフェニル)−4−メトキシ−3−(テトラヒドロ −3−フリルオキシ)ベンズアミド; N−(2,4,6−トリクロロフェニル)−4−メトキシ−3−(テトラヒドロ −3−フリルオキシ)ベンズアミド; N−(2,6−ジブロモフェニル)−4−メトキシ−3−(テトラヒドロ−3− フリルオキシ)ベンズアミド; N−(2−クロロ−6−メチルフェニル)−4−メトキシ−3−(テトラヒドロ −3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロフェニル)−4−メトキシ−3−(テトラヒドロ−3− フリルオキシ)ベンズアミド; N−(2フルオロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−フェニル−4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)ベンズ アミド; N−(2−メトキシフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリ ルオキシ)ベンズアミド; N−(2−クロロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(3−クロロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(4−メトキシフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリ ルオキシ)ベンズアミド; N−(2,6−ジメチルフェニル)−4−メトキシ−3−(テトラヒドロ−3− フリルオキシ)ベンズアミド; N−(2−メチルチオフェニル)−4−メトキシ−3−(テトラヒドロ−3−フ リルオキシ)ベンズアミド; N−(2−ブロモフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(2−メトキシカリボニルフェニル)−4−メトキシ−3−(テトラヒドロ −3−フリルオキシ)ベンズアミド; N−(2−アミノスルホニルフェニル)−4−メトキシ−3−(テトラヒドロ− 3−フリルオキシ)ベンズアミド; N−(2−ベンゾイルフェニル)−4−メトキシ−3−(テトラヒドロ−3−フ リルオキシ)ベンズアミド; N−(2−シアノフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(2,5−ジクロロフェニル)−4−メトキシ−3−(テトラヒドロ−3− フリルオキシ)ベンズアミド; N−(3−メチルフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(2−ニトロフェニル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−(2−ジメチルアミノフェニル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−(2−アセチルフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリ ルオキシ)ベンズアミド; N−(2−ヒドロキシフェニル)−4−メトキシ−3−(テトラヒドロ−3−フ リルオキシ)ベンズアミド; N−(2−メチルスルホニルフェニル)−4−メトキシ−3−(テトラヒドロ− 3−フリルオキシ)ベンズアミド; N−(2,6−ジフルオロフェニル)−4−メトキシ−3−(テトラヒドロ−4 H−ピラン−4−イルオキシ)ベンズアミド; N−(2,6−ジフルオロフェニル)−3−(2−エトキシエトキシ)−4−メ トキシベンズアミド; N−(2,6−ジフルオロフェニル)−4−メトキシ−3−(2−メトキシエト キシ)ベンズアミド; N−(2−クロロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)(チオベンズアミド); N−(4−クロロピリド−3−イル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−ピリド−2−イル−4−メトキシ−3−(テトラヒドロ−3−フリルオキシ )ベンズアミド; N−ピラジン−2−イル−4−メトキシ−3−(テトラヒドロ−3−フリルオキ シ)ベンズアミド; N−ピリミジン−2−イル−4−メトキシ−3−(テトラヒドロ−3−フリルオ キシ)ベンズアミド; N−(3−メチルピリド−2−イル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−ピリド−3−イル−4−メトキシ−3−(テトラヒドロ−3−フリルオキシ )ベンズアミド; N−(3−クロロピリド−2−イル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−(3−クロロピリド−4−イル)−4−メトキシ−3−(テトラヒドロ−3 −フリルオキシ)ベンズアミド; N−ピリド−4−イル−4−メトキシ−3−(テトラヒドロ−3−フリルオキシ )ベンズアミド; N−(3,5−ジメチルイソキサゾール−4−イル)−4−メトキシ−3−(テ トラヒドロ−3−フリルオキシ)ベンズアミド; 3−[2−(2−ブトキシエトキシ)エトキシ]−N−(3,5−ジクロロピリ ド−4−イル)−4−メトキシベンズアミド; N−(3,5−ジブロモピリド−4−イル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(2−エトキシエトキシ)− 4−メトキシベンズアミド; N−(3,5−ジメチルピリド−4−イル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−シアノフェニル)−4−メトキシ−3−(テトラ ヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−メトキシカルボニルフェニル)−4−メトキシ− 3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,3,5−トリフルオロピリド−4−イル)−4−メトキシ− 3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−エトキシカルボニルフェニル)−4−メトキシ− 3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−[(エキソ) −2−オキサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−[(エンド) −2−オキサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミド; N−(2,6−ジクロロ−4−ニトロフェニル)−4−メトキシ−3−(テトラ ヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジフルオロピリド−4−イル)−4−メトキシ−3−(テトラヒ ドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロフェニル)−4−メトキシ−3−[(エキソ)−2−オ キサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミド; N−(2,6−ジクロロフェニル)−4−メトキシ−3−[(エンド)−2−オ キサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(テトラヒドロ−3−フリル オキシ)−4−メトキシ−ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(テトラヒド ロ−2H−ピラン−2−メチルオキシ)ベンズアミド; N−(3−ブロモ−5−クロロピリド−4−イル)−4−メトキシ−3−(テト ラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(1−メトキ シプロポ−2−オキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(2−イソプロポキシエトキ シ)−4−メトキシベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(3−メトキ シ−1−ブトキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)(チオベンズアミド); N−(2,6−ジクロロ−4−アミノフェニル)−4−メトキシ−3−(テトラ ヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−アセチルアミノフェニル)−4−メトキシ−3− (テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−ホルミルフェニル)−4−メトキシ−3−(テト ラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−ヒドロキシメチルフェニル)−3−シクロペンチ ルオキシ−4−メトキシベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)ベンズアミドのナトリウム塩; N−(2,4,6−トリフルオロフェニル)−4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−メトキシフェニル)−4−メトキシ−3−(テト ラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロフェニル)−4−メトキシ−3−(7−オキサビシクロ [2.2.1]ヘプタン−2−オキシ)ベンズアミド; N−(4,6−ジクロロピリミド−5−イル)−4−メトキシ−3−(テ トラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,3,5,6−テトラフルオロピリド−4−イル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロ−2,6−ジフルオロピリド−4−イル)−4−メトキ シ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(5−シアノ−3−メチルイソチアゾール−4−イル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(2,6−ジクロロ−4−カルバモイルフェニル)−4−メトキシ−3−( テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(3−クロロ−2,5,6−トリフルオロピリド−4−イル)−4−メトキ シ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジブロモピリド−4−イル)−4−メトキシ−3−(エトキシエ トキシ)ベンズアミド; N−(4−ニトロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンズアミド; N−(3−メチル−5−ブロモイソチアゾール−4−イル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジメチルイソチアゾール−4−イル)−4−メトキシ−3−(テ トラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−(メチルチオ)−3−(テト ラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジフルオロピリド−4−イル)−4−(メチルチオ)−3−(テ トラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−(メチルチオ)−3−(7− オキサビシクロ[2.2.1]ヘプタン−2−オキシ)ベンズ アミド; N−(3,5−ジクロロピリド−4−イル)−4−(メチルチオ)−3−[(エ キソ )−2−オキサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミ ド; N−(3,5−ジクロロピリド−4−イル)−4−(メチルチオ)−3−[(エ ンド )−2−オキサビシクロ[2.2.1]ヘプタン−6−オキシ]ベンズアミ ド; N−(3,5−ジクロロピリド−4−イル)−3−(3,4−ジヒドロ−2H− ピラン−2−メトキシ)−4−メトキシベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(3,4−ジヒドロ−2H− ピラン−6−メトキシ)−4−メトキシベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−(フルオロメチルチオ)−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; 2′,6′−ジクロロベンジル=4−メトキシ−3−(テトラヒドロ−3−フリ ルオキシ)フェニル=ケトン; 3,5−ジクロロピリド−4−イルメチル=4−メトキシ−3−(テトラヒドロ −3−フリルオキシ)フェニル=ケトン; 3,5−ジクロロ−4−(2−(4−メトキシ−3−(テトラヒドロ−3−フリ ルオキシ)フェニル)−2−オキソエチル)ピリジン−N−オキシド; 2−(3−クロロピリド−4−イル)−1−(4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)フェニル)エタノン; 1−(4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル)−2 −(4−ピリジル)エタノン; 1−(4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニ ル)−2−フェニルエタノン; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(4−メトキ シ−3−メチルブト−1−エン−3−オキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(7−オキサ ビシクロ−[2.2.1]ヘプト−5−エン−2−オキシ)ベンズアミド; N−(4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル)−2 ,6−ジクロロベンズアミド; N−[4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル]−2 ,6−ジフルオロベンズアミド; N−(2,6−ジクロロフェニル)−N′−(4−メトキシ−3−(テトラヒド ロ−3−フリルオキシ)フェニル)−尿素; N−(3,5−ジクロロピリド−4−イル)−N′−(4−メトキシ−3−(テ トラヒドロ−3−フリルオキシ)フェニル)尿素; 4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル=2,6−ジ クロロベンゾアート; 2,6−ジクロロベンジル=4−メトキシ−3−(テトラヒドロ−3−フリルオ キシ)フェニル=エーテル; N−(2−クロロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンジルアミン; トランス−2−(2,6−ジクロロフェニル)−1−(メトキシ−3−(テトラ ヒドロ−3−フリルオキシ)フェニル)エテン; トランス−2−(2,6−ジフルオロフェニル)−1−(4−メトキシ−3−( テトラヒドロ−3−フリルオキシ)フェニル)エテン; 1−[(4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェ ニル]−2−(ピリド−4−イル)エタン−1,2−ジオン; トランス−2−(3,5−ジクロロピリド−4−イル)−1−(4−メトキシ− 3−(テトラヒドロ−3−フリルオキシ)フェニル)ジアゼン1−(4−メトキ シ−3−(テトラヒドロ−3−フリルオキシ)フェニル)−c−1−オキソ−r −2−(3,5−ジクロロ−1−オキソピリド−4−イル)ジアゼン; トランス−1−(4−メトキシ−3−(テトラヒドロ−3−フリルオキシ)フェ ニル)−2−(3,5−ジクロロ−1−オキソピリド−4−イル)ジアゼン; N−(2−クロロフェニル)−4−メトキシ−3−(テトラヒドロ−3−フリル オキシ)ベンゼン−スルフォンアミド; N−(3,5−ジクロロピリド−4−イル)−3−(テトラヒドロ−3−フリル オキシ)−4−トリフルオロメトキシ−ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(4,4−ジメチル−3,5 ,10−トリオキサトリシクロ−[5.2.1.02,6]デカン−8−オキシ) −4−メトキシベンズアミド; N−(3,5−ジフルオロピリド−4−イル)−4−ジフルオロメトキシ−3− (1−メトキシ−プロポ−2−オキシ)ベンズアミド; N−(3,5−ジフルオロ−1−オキシド−4−ピリジニオ)−4−ジフルオロ メトキシ−3−(1−メトキシ−プロポ−2−オキシ)ベンズアミド; N−(3,5−ジクロロ−ピリド−4−イル)−4−ジフルオロメトキシ−3− (1−メトキシ−プロポ−2−オキシ)ベンズアミド; N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−ジフ ルオロメトキシ−3−(1−メトキシ−プロポ−2−オキシ)ベンズアミド; N−(3,5−ジクロロ−4−ピリジル)−4−ジフルオロメトキシ−3−(7 −オキサ−ビシクロ[2.2.1]ヘプタン−2−オキシ)ベンズアミド; N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−ジフルオロメ トキシ−3−(7−オキサ−ビシクロ[2.2.1]ヘプタン−2−オキシ)ベ ンズアミド; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−[2−(プロ ポ−2−イン−1−オキシ)エトキシ]−ベンズアミド; N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−3−(4,4−ジ メチル−3,5,10−トリオキサトリシクロ−[5.2.1.02,6]デカン −8−オキシ)−4−メトキシベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(1−メトキシプロポ−2− オキシ)−4−(メトキシチオ)−ベンズアミド; N−(3,5−ジフルオロピリド−4−イル)−3−(1−メトキシプロポ−2 −オキシ)−4−(メトキシチオ)−ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−3−(3−メトキシブトキシ)− 4−(メチルチオ)ベンズアミド; 2−(3,5−ジクロロピリド−4−イル)−1−[4−メトキシ−3−(7− オキサビシクロ[2.2.1]ヘプタン−2−オキシ)フェニル]エタノン; 2−(3,5−ジクロロピリド−4−イル)−1−[4−(メチルチオ)−3− (テトラヒドロ−3−フリルオキシ)フェニル]エタノン; 2−(3,5−ジクロロピリド−4−イル)−1−[4−メトキシ−3 −(テトラヒドロ−4H−ピラン−4−イルオキシ)−フェニル)エタノン;( JD) 2−(3,5−ジクロロピリド−4−イル)−1−(4−メチルチオ− 3−(テトラヒドロ−4H−ピラン−4−イルオキシ)−フェニル)エタノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−メトキ シ−3−(テトラヒドロ−4H−ピラン−4−イルオキシ)フェニル)エタノン ; 1−(4−ジフルオロメトキシ−3−(テトラヒドロ−3−フリルオキシ)フェ ニル)−2−(3,5−ジクロロピリド−4−イル)−エタノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−ジフル オロメトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル)エタノン; 2−(3,5−ジクロロピリド−4−イル)−1−(4−メトキシ−3−(7− オキサビシクロ[2.2.1]ヘプタン−5−エン−2−オキシ)フェニル]エ タノン; 2−(3,5−ジクロロ−4−ピリジル)−1−(4−ジフルオロメトキシ−3 −(7−オキサビシクロ[2.2.1]ヘプタン−2−オキシ)フェニル)エタ ノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−ジフル オロメトキシ−3−(7−オキサビシクロ−[2.2.1]ヘプタン−2−オキ シ)フェニル)エタノン; 2−(3,5−ジクロロ−4−ピリジル)−1−[3−(2−イソプロポキシエ トキシ)−4−メトキシフェニル]エタノン; 2−(3,5−ジクロロ−4−ピリジル)−1−(4−ジフルオロメト キシ−3−(1−メトキシプロポ−2−オキシ)フェニル)エタノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−ジフル オロメトキシ−3−(1−メトキシプロポ−2−オキシ)フェニル)エタノン; 3,5−ジクロロ−4−(4−メトキシ−3−(テオラヒドロ−3−フリルオキ シ)フェノキシ−メチル)ピリジン; N−3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−メトキシ−3− (7−オキサビシクロ[2.2.1]ヘプタン−2−オキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−6−フルオロ−4−メトキシ−3 −(テオラヒドロ−3−フリルオキシ)ベンズアミド; N−(3,5−ジクロロピリド−4−イル)−6−メトキシ−5−(テオラヒド ロ−3−フリルオキシ)ニコチンアミド; N−(2,6−ジクロロピリド−4−イル)−6−メトキシ−5−(テオラヒド ロ−3−フリルオキシ)ニコチンアミド; N−(3,5−ジフルオロピリド−4−イル)−6−メトキシ−5−(テオラヒ ドロ−3−フリルオキシ)ニコチンアミド; N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−6−(テオラヒド ロ−3−フリルオキシ)ピリジン−2−カルボキサミド; N−(3,5−ジメチルイソキサゾール−4−イル)−6−メトキシ−5−(テ オラヒドロ−3−フリルオキシ)ニコチンアミド; 2−(3,5−ジクロロピリド−4−イル)−1−(6−メトキシ−5−(テオ ラヒドロ−3−フリルオキシ)ピリド−3−イル)エタノン; N−(3,5−ジクロロピリド−4−イル)−6−(メチルチオ)−5−(テオ ラヒドロ−3−フリルオキシ)ニコチンアミド; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(6−メトキ シ−5−(テオラヒドロ−3−フリルオキシ)ピリド−3−イル)エタノン; N−(3,5−ジクロロピリド−4−イル)−5−(1−メトキシプロポ−2− オキシ)−6−(メチルチオ)ニコチンアミド; 2−(3,5−ジクロロピリド−4−イル)−1−[5−(1−メトキシプロポ −2−オキシ)−6−(メチルチオ)ピリド−3−イル]エタノン; (S)−(+)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; (R)−(−)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−メト キシ−3−(1−メトキシプロポ−2−イルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−4−(テ トラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−5−メト キシ−4−(テトラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド ; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−1−オキ シド−4−(テトラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド ; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)− 5−メトキシ−1−オキシド−4−(テトラヒドロ−3−フリルオキシ)−2− ピリジンカルボキサミド; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−4−(テ トラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド; (±)−(5−メトキシ−4−(テトラヒドロ−3−フリルオキシ)ピリド−2 −イル)−2−(3,5−ジクロロピリド−4−イル)エタノン;および (±)−(5−メトキシ−4−(テトラヒドロ−3−フリルオキシ)ピリド−2 −イル)−2−(3,5−ジクロロ−1−オキシド−4−ピリジル)エタノン; である請求項1に記載の化合物。 21.(±)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3−(テト ラヒドロ−4−ピラニルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−メト キシ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−4−ピリジル)−4−ジフルオロメトキシ− 3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−ピリジノ)−4−ジフルオロ メトキシ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (S)−(+)−N−(3,5−ジクロロ−4−ピリジル)−4−メト キシ−3−(テトラヒドロ−3−フリルオキシ)ベンズアミド; (R)−(−)−N−(3,5−ジクロロ−4−ピリジル)−4−メトキシ−3 −(テトラヒドロ−3−フリルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−メト キシ−3−(1−メトキシプロポ−2−イルオキシ)ベンズアミド; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−4−(テ トラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−5−メト キシ−4−(テトラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド ; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−1−オキ シド−4−(テトラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド ; (±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−5−メト キシ−1−オキシド−4−(テトラヒドロ−3−フリルオキシ)−2−ピリジン カルボキサミド; (±)−N−(3,5−ジクロロピリド−4−イル)−5−メトキシ−4−(テ トラヒドロ−3−フリルオキシ)−2−ピリジンカルボキサミド; (±)−(5−メトキシ−4−(テトラヒドロ−3−フリルオキシ)ピリド−2 −イル)−2−(3,5−ジクロロピリド−4−イル)エタノン; (±)−(5−メトキシ−4−(テトラヒドロ−3−フリルオキシ)ピ リド−2−イル)−2−(3,5−ジクロロ−1−オキシド−4−ピリジル)エ タノン; N−(3,5−ジクロロピリド−4−イル)−4−メトキシ−3−(1−メトキ シプロポ−2−オキシ)ベンズアミド; 1−(4−ジフルオロメトキシ−3−(テトラヒドロ−3−フリルオキシ)フェ ニル)−2−(3,5−ジクロロピリド−4−イル)−エタノン;または 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−ジフル オロメトキシ−3−(テトラヒドロ−3−フリルオキシ)フェニル)エタノン である請求項20に記載の化合物。 22.(±)−N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)− 5−メトキシ−1−オキシド−4−(テトラヒドロ−3−フリルオキシ)−2− ピリジンカルボキサミドである請求項21に記載の化合物。 23.薬学的許容量の請求項1に記載の化合物と薬学的に許容される担体とを 含んでなる医薬組成物。 24.腫瘍壊死因子(TNF)を阻害することによって変調させることができ る疾患状態を治療する方法において、前記疾患状態に罹っている患者に請求項1 に記載の化合物の有効量を投与することを含んでなる疾患状態の治療方法。 25.疾患状態が炎症性疾患または自己免疫性疾患である請求項24に記載の 方法。 26.疾患状態が、関節炎症、関節炎、リウマチ様関節炎、リウマチ様脊髄炎 および骨関節炎、敗血症、敗血性ショック、グラム陰性敗血症、 トキシックショック症候群、急性呼吸窮迫症候群、喘息、骨吸収疾患、再散布傷 害、移植片対宿主反応、同種異型移植拒絶マラリア、筋痛、エイズウイルス(H IV)、エイズ(AIDS)、悪液質、限定性回腸炎、潰瘍性大腸炎、パイレシ ス(pyresis)、全身性エリテマトーデス、多発性硬化症、I型真性糖尿 病、乾癬、ベーチェト病、アナフィラキシー性紫斑腎炎、慢性糸球体腎炎、炎症 性腸疾患および白血症よりなる群から選択される請求項24に記載の方法。 27.疾患状態が関節炎症である請求項26に記載の方法。 28.サイクリックAMPホスホジエステラーゼの産生を阻害することによっ て変調させることができる疾患状態を治療する方法において、前記疾患状態に罹 っている患者に請求項1で示される化合物の有効量を投与することを含んでなる 疾患状態の治療方法。 29.疾患状態が、サイクリックAMPホスホジエステラーゼの作用、好酸球 の蓄積または好酸球の作用に関連する病理学的症状である請求項28に記載の方 法。 30.病理学的症状が、喘息、アトピー性皮膚炎、じんま疹、アレルギー性鼻 炎、乾癬、リウマチ様関節炎、潰瘍性大腸炎、限定性回腸炎、成人呼吸窮迫症候 群、尿崩症、角化症、皮膚炎、大脳老化、多発脳梗塞性痴呆、老年性痴呆、パー キンソン病に関連する記憶障害、心動停止、発作および間欠性験行である請求項 29に記載の方法。 31.病理学的症状が喘息である請求項30に記載の方法。 32.実質的に上記の通りである請求項1に記載の化合物の製造方法。 33.実施例に関連する請求項1に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9401460.2 | 1994-01-26 | ||
GB9401460A GB9401460D0 (en) | 1994-01-26 | 1994-01-26 | Compositions of matter |
PCT/GB1995/000157 WO1995020578A1 (en) | 1994-01-26 | 1995-01-26 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509654A true JPH09509654A (ja) | 1997-09-30 |
JP3953096B2 JP3953096B2 (ja) | 2007-08-01 |
Family
ID=10749342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51993995A Expired - Lifetime JP3953096B2 (ja) | 1994-01-26 | 1995-01-26 | サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0741707B1 (ja) |
JP (1) | JP3953096B2 (ja) |
AT (1) | ATE164575T1 (ja) |
AU (1) | AU1463195A (ja) |
DE (1) | DE69501947T2 (ja) |
GB (1) | GB9401460D0 (ja) |
IL (1) | IL112462A0 (ja) |
WO (1) | WO1995020578A1 (ja) |
ZA (1) | ZA95639B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002509927A (ja) * | 1998-04-01 | 2002-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pdeiv阻害ピリジン誘導体 |
JP2006508987A (ja) * | 2002-11-19 | 2006-03-16 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ4阻害剤 |
JP2008543781A (ja) * | 2005-06-10 | 2008-12-04 | メモリー・ファーマシューティカルズ・コーポレイション | ホスフオジエステラーゼ4阻害剤 |
JP2010513334A (ja) * | 2006-12-22 | 2010-04-30 | レオ ファーマ アクティーゼルスカブ | Pde4阻害剤として有用な置換アセトフェノン |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2160928C (en) | 1993-07-28 | 2005-07-05 | Garry Fenton | Compounds as pde iv and tnf inhibitors |
US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
TW375612B (en) * | 1995-04-06 | 1999-12-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
GB9507297D0 (en) * | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
WO1997003967A1 (en) * | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
DE19628622A1 (de) * | 1996-07-16 | 1998-01-22 | Byk Gulden Lomberg Chem Fab | Neue 5-substituierte [2H] Chromene |
DE19628621A1 (de) * | 1996-07-16 | 1998-01-22 | Byk Gulden Lomberg Chem Fab | Neue 4-substituierte Benzofurane |
KR100338610B1 (ko) | 1996-09-04 | 2002-05-27 | 디. 제이. 우드, 스피겔 알렌 제이 | 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도 |
EP0882714B1 (en) * | 1996-09-25 | 2004-03-03 | SS Pharmaceutical Co., Ltd. | Substituted vinylpyridine derivatives and drugs containing the same |
PL194673B1 (pl) * | 1996-10-02 | 2007-06-29 | Janssen Pharmaceutica Nv | Pochodna 2-cyjanoiminoimidazolu, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna |
AU5337498A (en) * | 1997-01-22 | 1998-08-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted beta-thiocarboxylic acids |
DE69835594T2 (de) | 1997-02-17 | 2007-08-16 | Altana Pharma Ag | Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten |
DE19705924A1 (de) * | 1997-02-17 | 1998-08-27 | Byk Gulden Lomberg Chem Fab | Neue Zusammensetzungen |
PT1027328E (pt) | 1997-10-31 | 2006-11-30 | Aventis Pharma Ltd | Anilidas substituídas |
PT1086096E (pt) | 1998-06-10 | 2003-12-31 | Altana Pharma Ag | Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4 |
JP5038568B2 (ja) | 1999-08-21 | 2012-10-03 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 協力剤の組合せ物 |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
KR20040007583A (ko) | 2001-05-23 | 2004-01-24 | 다나베 세이야꾸 가부시키가이샤 | 연골 질환의 재생치료용 조성물 |
MXPA03010679A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Una composicion para acelerar la cicatrizacion de fractura osea. |
CA2451955C (en) | 2001-06-26 | 2015-09-29 | Abgenix, Inc. | Antibodies to opgl |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
BR0313000A (pt) | 2002-07-19 | 2005-07-12 | Memory Pharm Corp | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente |
EP1539697A1 (en) | 2002-07-19 | 2005-06-15 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
BR0314721A (pt) | 2002-10-23 | 2005-08-02 | Glenmark Pharmaceuticals Ltd | Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os |
JP2006517191A (ja) | 2002-12-30 | 2006-07-20 | アムジエン・インコーポレーテツド | 共刺激因子を用いた併用療法 |
US7615575B2 (en) | 2003-02-13 | 2009-11-10 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
BRPI0409229A (pt) | 2003-04-01 | 2006-03-28 | Applied Research Systems | inibidores das fosfodiesterases na infertilidade |
DE602004020332D1 (de) | 2003-04-11 | 2009-05-14 | Glenmark Pharmaceuticals Sa | Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
EP1799632A2 (en) | 2004-10-13 | 2007-06-27 | Glenmark Pharmaceuticals S.A. | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
SI1831227T1 (sl) | 2004-12-17 | 2013-09-30 | Glenmark Pharmaceuticals S.A. | Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj |
MX2007007345A (es) | 2004-12-17 | 2007-09-07 | Glenmark Pharmaceuticals Sa | Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos. |
UA96783C2 (ru) * | 2006-12-22 | 2011-12-12 | Лео Фарма А/С | Замещенные метилфенилкетоны, пригодные для использования как ингибиторы pde4 |
FR2915098B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere |
FR2915099B1 (fr) | 2007-04-19 | 2009-06-05 | Sanofi Aventis Sa | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens |
AR076221A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
GB201113689D0 (en) | 2011-08-09 | 2011-09-21 | Amakem Nv | Novel PDE4 inhibitors |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
CN113181161A (zh) | 2013-04-18 | 2021-07-30 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0641455B2 (ja) * | 1984-12-10 | 1994-06-01 | 日産化学工業株式会社 | ピリダジノン誘導体 |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
DK0607373T3 (da) * | 1992-06-15 | 1997-10-13 | Celltech Therapeutics Ltd | Trisubstituerede phenylderivater som selektive phosphodiesterase IV-inhibitorer. |
CA2140441C (en) * | 1992-07-28 | 2006-11-21 | Garry Fenton | Inhibitors of c-amp phosphodiesterase and tnf |
-
1994
- 1994-01-26 GB GB9401460A patent/GB9401460D0/en active Pending
-
1995
- 1995-01-26 IL IL11246295A patent/IL112462A0/xx unknown
- 1995-01-26 WO PCT/GB1995/000157 patent/WO1995020578A1/en active IP Right Grant
- 1995-01-26 JP JP51993995A patent/JP3953096B2/ja not_active Expired - Lifetime
- 1995-01-26 DE DE69501947T patent/DE69501947T2/de not_active Expired - Lifetime
- 1995-01-26 ZA ZA95639A patent/ZA95639B/xx unknown
- 1995-01-26 AU AU14631/95A patent/AU1463195A/en not_active Abandoned
- 1995-01-26 AT AT95906437T patent/ATE164575T1/de active
- 1995-01-26 EP EP95906437A patent/EP0741707B1/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002509927A (ja) * | 1998-04-01 | 2002-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pdeiv阻害ピリジン誘導体 |
JP4778612B2 (ja) * | 1998-04-01 | 2011-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Pdeiv阻害ピリジン誘導体 |
JP2006508987A (ja) * | 2002-11-19 | 2006-03-16 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ4阻害剤 |
JP2008543781A (ja) * | 2005-06-10 | 2008-12-04 | メモリー・ファーマシューティカルズ・コーポレイション | ホスフオジエステラーゼ4阻害剤 |
JP2010513334A (ja) * | 2006-12-22 | 2010-04-30 | レオ ファーマ アクティーゼルスカブ | Pde4阻害剤として有用な置換アセトフェノン |
Also Published As
Publication number | Publication date |
---|---|
ATE164575T1 (de) | 1998-04-15 |
EP0741707A1 (en) | 1996-11-13 |
DE69501947T2 (de) | 1998-08-27 |
EP0741707B1 (en) | 1998-04-01 |
ZA95639B (en) | 1996-07-26 |
GB9401460D0 (en) | 1994-03-23 |
JP3953096B2 (ja) | 2007-08-01 |
AU1463195A (en) | 1995-08-15 |
DE69501947D1 (de) | 1998-05-07 |
IL112462A0 (en) | 1995-03-30 |
WO1995020578A1 (en) | 1995-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509654A (ja) | サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物 | |
JP3775684B2 (ja) | 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物 | |
JP3775685B2 (ja) | Pde▲iv▼およびtnf抑制剤としての化合物 | |
US6255326B1 (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group | |
CA2150812C (en) | Catechol diethers as selective pde iv inhibitors | |
JP2664538B2 (ja) | ベンズアミド | |
US5935978A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | |
US5679696A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group | |
DE60132618T2 (de) | 4,6-diphenylpyridinderivate als entzündungshemmende mittel | |
JP2001521926A (ja) | 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換 | |
JP2004083583A (ja) | ニコチンアミド誘導体 | |
AU2007262426A1 (en) | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | |
JP2000509719A (ja) | 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用 | |
JP2020533328A (ja) | ベンゼン縮合複素環誘導体およびその医薬組成物 | |
JP2010059169A (ja) | カンナビノイドレセプターリガンド | |
JP2000501411A (ja) | ベンゾフランカルボキサミドおよびスルホンアミド | |
US6096768A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | |
KR102378883B1 (ko) | 아미드 화합물 및 그 용도 | |
NZ755328B2 (en) | Amide compounds and use thereof | |
HU211979A9 (hu) | Arii- vagy heteroaril-csoporthoz egy alifás, vagy heteroatomot tartalmazó, összekötő csoporton át kapcsolódó, fenilcsoportot tartalmazó vegyületek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060306 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070410 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070424 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110511 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110511 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120511 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130511 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130511 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |